Primary care physician beliefs about insulin initiation in patients with type 2 diabetes

por Hayes, R P, Fitzgerald, J T, Jacober, S J
Publicado 2008

A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction: A reanalysis of the HEART2D study

por Siegelaar, Sarah E., Kerr, Lisa, Jacober, Scott J., Devries, J. Hans
Publicado 2011

Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes

por de Leon, Ella M, Jacober, Scott J, Sobel, Jack D, Foxman, Betsy
Publicado 2002

Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism

por Moore, Mary Courtney, Smith, Marta S., Sinha, Vikram P., Beals, John M., Michael, M. Dodson, Jacober, Scott J., Cherrington, Alan D.
Publicado 2014

Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia

por Raz, Itamar, Ceriello, Antonio, Wilson, Peter W., Battioui, Chakib, Su, Eric W., Kerr, Lisa, Jones, Cate A., Milicevic, Zvonko, Jacober, Scott J.
Publicado 2011

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes

por Bergenstal, Richard M., Rosenstock, Julio, Arakaki, Richard F., Prince, Melvin J., Qu, Yongming, Sinha, Vikram P., Howey, Daniel C., Jacober, Scott J.
Publicado 2012

Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treate...

por Bergenstal, Richard M., Rosenstock, Julio, Arakaki, Richard F., Prince, Melvin J., Qu, Yongming, Sinha, Vikram P., Howey, Daniel C., Jacober, Scott J.
Publicado 2013

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

por Rosenstock, Julio, Bergenstal, Richard M., Blevins, Thomas C., Morrow, Linda A., Prince, Melvin J., Qu, Yongming, Sinha, Vikram P., Howey, Daniel C., Jacober, Scott J.
Publicado 2013

Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGI...

por Bergenstal, R. M., Lunt, H., Franek, E., Travert, F., Mou, J., Qu, Y., Antalis, C. J., Hartman, M. L., Rosilio, M., Jacober, S. J., Bastyr, E. J.
Publicado 2016

Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial

por Davies, M. J., Russell‐Jones, D., Selam, J.‐L., Bailey, T. S., Kerényi, Z., Luo, J., Bue‐Valleskey, J., Iványi, T., Hartman, M. L., Jacobson, J. G., Jacober, S. J.
Publicado 2016

Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial

por Raz, Itamar, Wilson, Peter W.F., Strojek, Krzysztof, Kowalska, Irina, Bozikov, Velimir, Gitt, Anselm K., Jermendy, György, Campaigne, Barbara N., Kerr, Lisa, Milicevic, Zvonko, Jacober, Scott J.
Publicado 2009